
COLLABORATION WITH MICRON INC., TO ENTER JAPANESE MARKET

Highlights

- Collaboration agreement signed with Toyko, Japan, based Micron, Inc. to feature Resonance Health's imaging analysis products and services within the Japanese market.
 - Increased access and exposure to Japanese biopharmaceutical companies conducting clinical trials in Japan, and to Japanese medical institutions, via Micron's network.
 - Represents Resonance Health's entry into the Japanese market for the provision of products and services for diagnostic usage.
-

Resonance Health Ltd (ASX: RHT) (**Resonance** or **Company**) is pleased to announce that it has signed a Memorandum of Understanding & License Agreement (**Collaboration Agreement**) with Tokyo, Japan, headquartered Micron, Inc., a global leader in the provision of medical imaging solutions to CROs and biopharmaceutical companies' conducting clinical trials (**Micron**).

About Micron

Micron is a molecular imaging contract research organisation (**CRO**) that provides medical imaging technical and clinical trial support services. It offers image analysis, PET tracer manufacturing, and site management services for a multitude of clinical trials including large multi-centre clinical trials. Micron has assisted over 250 customers in the development and launch to market of more than 40 drugs. It achieves this through using a range of imaging services to develop pharmaceuticals, diagnostics, and biomarkers; and clinical development, such as monitoring, quality control, image analysis, handling, and image reading. In 2021 Micron established the INDICATE program (**I**nnovative **D**iagnostic **I**maging **C**apabilities **A**dooption **T**o **E**nd-users) which forms a bridge between international imaging specialist companies and the Japanese market to enhance uptake of new technologies, including artificial intelligence (**AI**) powered and trained technologies. For further information on Micron please visit, <https://micron-kobe.com/en>

Strategy

The Collaboration Agreement progresses the Company's strategy of expanding into new geographies for both clinical trial and diagnostic services. Liver cirrhosis aetiologies in Japan are increasing in step with an increase in alcoholic-related disease (**ALD**) and non-alcoholic steatohepatitis (**NASH**). Furthermore, Japan is among the largest pharmaceutical markets in the world with sales revenues totalling over USD \$100 billion in 2021 for the sale of both prescription and non-prescription pharmaceuticals. Working with an established entity with over 20 years of experience in CRO services in the Japanese market will assist in Resonance's fast-tracking of growth in Japan for both its clinical trial and diagnostic services.

Resonance CEO, Andrew Harrison stated:

"We are delighted to be partnering with Micron. Micron has built a truly great business with service provision to over 250 customers and our collaboration with them represents a great opportunity to deliver products and services into the large and lucrative Japanese market."

Further particulars of the Collaboration Agreement are included at [Annex A](#).

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Ltd. For further information please contact:

Andrew Harrison – Chief Executive Officer

E: andrewh@resonancehealth.com

P: +61 (0)8 9286 5300

About Resonance Health

Resonance Health is an Australian healthcare technology and services company. The Company's services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high quality quantitative assessments essential in managing diseases and drug development.

Resonance Health's dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (**SaMDs**) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (**AI**), include:

- **FerriScan®**, a core-lab product that provides an accurate assessment of liver iron concentration (**LIC**) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment.
- **FerriSmart®**, an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in patients, calibrated against the global gold standard, FerriScan®.
- **HepaFatSmart®**, an AI-trained, non-invasive device for the automated real-time multi-metric assessment of liver-fat in patients, for the assessment of individuals with confirmed or suspected fatty liver disease.
- **LiverSmart®**, an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFat-AI® into a consolidated report providing accurate assessment of LIC and liver fat.
- **CardiacT2***, the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2*.

The Company has a development pipeline of additional medical imaging analysis products and services, including the **MRI Liver Fibrosis Project**, aimed at accurately assessing the presence and progression of liver fibrosis utilising non-invasive MRI analysis.

Stakeholders, including clinicians, patients, and shareholders, are encouraged to register their interest at www.resonancehealth.com and to follow Resonance Health on Facebook, LinkedIn, and Twitter.

FOLLOW US



/Resonance-Health-Ltd



/ResonanceHealth



/ResonanceHealthLtd

ANNEX A

Details of Collaboration Agreement

The Collaboration Agreement permits Micron to provide information on the full range of the Company's medical imaging products and services via the INDICATE platform or through introductions to Micron's customers including its clinical trial partners.

To facilitate this, and as the sole consideration for this, the Company has granted Micron a revocable license to use its name and its trademarks and logos including FerriScan®, FerriSmart®, HepaFatScan®, HefaFatSmart®, and LiverSmart®.

Micron is under no obligation to continue promoting the Company's products on INDICATE or to provide introductions to its partners and it does so on a voluntary basis, and only when it considers those services may be beneficial for its customers.

Any future contract for service provision will be between Resonance and the end-user-customer and Micron will not receive any commission or incentive for any such agreements entered between the Company and new customers introduced by Micron or via INDICATE.

Either party may terminate the Collaboration Agreement by notifying the other party in writing at which time the Company's products will cease to be featured on INDICATE or promoted by Micron, and the license to use the Company's trademarks will expire.